Humacyte, Inc. 8-K

What Happened

• On April 21, 2026 Humacyte, Inc. announced a Third Amendment to its Distribution Agreement with Fresenius Medical Care Holdings, Inc., reverting the ex‑U.S. development and commercialization rights for Humacyte’s 6 millimeter acellular tissue‑engineered vessel (the “Distribution Product”) back to Humacyte. Under the amendment Humacyte now has the sole right to develop, commercialize and handle regulatory matters for the Distribution Product worldwide.
• The company will pay Fresenius low‑single‑digit royalties on net sales outside the U.S., subject to a two‑year royalty‑free period following product launch in each country. Humacyte will continue to pay U.S. royalties at rates ranging from mid‑single digits to low‑double digits. Fresenius remains obligated to adopt the Distribution Product as a standard of care for appropriate hemodialysis patients where clinical and economic data support such use. Humacyte furnished a related press release on April 24, 2026.

Key Details

• Agreement amendment date: April 21, 2026 (Third Amendment to original June 25, 2018 Distribution Agreement).
• Product: 6 mm acellular tissue‑engineered vessel (Distribution Product).
• Royalty terms: low‑single‑digit royalties ex‑U.S. (with a two‑year royalty‑free window after launch in each country); U.S. royalties remain mid‑single to low‑double digits.
• Commercial commitment: Fresenius retains obligation to adopt the product as a standard of care where supported by results and health‑economic analyses.

Why It Matters

• Regaining global commercial and regulatory control can give Humacyte direct control over development plans, approval strategies and commercialization decisions outside the U.S., which could accelerate launches or align global strategy.
• The royalty payments mean Humacyte will still share a portion of future sales with Fresenius, but the two‑year country‑level royalty‑free launch window may improve near‑term economics in new markets.
• For investors, the deal shifts commercialization upside and execution risk back to Humacyte while maintaining a channel partner commitment from Fresenius to support clinical adoption where warranted; key upcoming milestones to watch include regulatory filings, launch timing by country, and any disclosed sales guidance.